Based on this, we established a risk model for Chinese AML patients, which included age, sex, mutations (NPM1, RUNX1, SH2B3, and TP53), and fusions (CBFB::MYH11 and RUNX1::RUNX1T1). Here, TP53 is linked to acute myeloid leukemia.